European inter-institutional impact study of MammaPrint

Autor: Cusumano, P.G., Generali, D., Ciruelos, E., Manso, L., Ghanem, I., Lifrange, E., Jerusalem, G., Klaase, J., de Snoo, F., Stork-Sloots, L., Dekker-Vroling, L., Holzik, M. Lutke

Publikováno v: In The Breast August 2014 23(4):423-428

MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials

Autor: Cristofanilli, M., de Snoo, F., Stork-Sloots, L., Hansen, T., Garay, C.A., Lazaro, S., Chabut, D., Picardo, F., Warren-Mora, N., Kuhr, F., Spinner, D.

Publikováno v: In Value in Health December 2023 26(12) Supplement:S433-S433

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.

Autor: Viale, G., de Snoo, F. A., Slaets, L., Bogaerts, J., van ’t Veer, L., Rutgers, E. J., Piccart-Gebhart, M. J., Stork-Sloots, L., Glas, A., Russo, L., Dell’Orto, P., Tryfonidis, K., Litière, S., Cardoso, F., for the MINDACT investigators

Publikováno v: Breast Cancer Research & Treatment; Jan2018, Vol. 167 Issue 1, p123-131, 9p

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.

Autor: Biran N; Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey USA., Dhakal B; Division of Hematology and Oncology Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA., Lentzsch S; Division of Hematology and Oncology Herbert Irving Comprehensive Cancer Center Columbia University New York New York USA., Siegel D; Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey USA., Usmani SZ; Levine Cancer Institute Charlotte North Carolina USA., Rossi A; Department of Medical Oncology New York Presbyterian Hospital-Weill Cornell Medical Center Weill Cornell Medicine New York New York USA., Rosenbaum C; Department of Medical Oncology New York Presbyterian Hospital-Weill Cornell Medical Center Weill Cornell Medicine New York New York USA., Bhutani D; Division of Hematology and Oncology Herbert Irving Comprehensive Cancer Center Columbia University New York New York USA., Vesole DH; Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey USA.; Multiple Myeloma Program Lombardi Comprehensive Cancer Center & Medstar Georgetown University Hospital Georgetown University Washington District of Columbia USA., Rodriguez C; Wake Forest Baptist Comprehensive Cancer Center Winston-Salem North Carolina USA., Nooka AK; Winship Cancer Institute Emory University Atlanta Georgia USA., van Rhee F; Myeloma Center University of Arkansas of Medical Sciences Little Rock Arkansas USA., Stork-Sloots L; Medex15 Amsterdam The Netherlands., de Snoo F; Medex15 Amsterdam The Netherlands., Bhattacharyya PK; Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey USA., Dash DP; Versiti Blood Center of Wisconsin Milwaukee Wisconsin USA., Zümrütçü S; SkylineDx Rotterdam The Netherlands., van Vliet MH; SkylineDx Rotterdam The Netherlands., Hari P; Division of Hematology and Oncology Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA., Niesvizky R; Department of Medical Oncology New York Presbyterian Hospital-Weill Cornell Medical Center Weill Cornell Medicine New York New York USA.

Publikováno v: EJHaem [EJHaem] 2021 May 11; Vol. 2 (3), pp. 375-384. Date of Electronic Publication: 2021 May 11 (Print Publication: 2021).